Free Trial
→ Iran's New Leader Just Said Something That Should Terrify Every American (From American Alternative) (Ad)tc pixel Free BACK Stock Alerts

IMAC (BACK) Competitors

IMAC logo
$0.04 0.00 (-9.30%)
As of 02:41 PM Eastern
Compare

BACK vs. DHAC, NIVF, BTTX, UPHL, and ACONW

Should you be buying IMAC stock or one of its competitors? The main competitors of IMAC include Digital Health Acquisition (DHAC), NewGenIvf Group (NIVF), Better Therapeutics (BTTX), UpHealth (UPHL), and Aclarion (ACONW). These companies are all part of the "healthcare" industry.

How does IMAC compare to Digital Health Acquisition?

Digital Health Acquisition (NASDAQ:DHAC) and IMAC (NASDAQ:BACK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Digital Health Acquisition has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, IMAC has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.

Digital Health Acquisition has higher earnings, but lower revenue than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Digital Health AcquisitionN/AN/AN/AN/AN/A
IMAC$72.05K2.05-$9.42M-$3.12N/A

In the previous week, IMAC had 1 more articles in the media than Digital Health Acquisition. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Digital Health Acquisition. Digital Health Acquisition's average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Digital Health Acquisition Neutral
IMAC Neutral

Company Net Margins Return on Equity Return on Assets
Digital Health AcquisitionN/A N/A N/A
IMAC N/A N/A -325.44%

1.0% of Digital Health Acquisition shares are owned by institutional investors. Comparatively, 5.8% of IMAC shares are owned by institutional investors. 6.6% of Digital Health Acquisition shares are owned by company insiders. Comparatively, 12.3% of IMAC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

IMAC beats Digital Health Acquisition on 5 of the 6 factors compared between the two stocks.

How does IMAC compare to NewGenIvf Group?

IMAC (NASDAQ:BACK) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

5.8% of IMAC shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 12.3% of IMAC shares are held by company insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IMAC
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
NewGenIvf Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

IMAC has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.

NewGenIvf Group has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.05-$9.42M-$3.12N/A
NewGenIvf Group$4.73M0.08$9.88MN/AN/A

In the previous week, NewGenIvf Group had 1 more articles in the media than IMAC. MarketBeat recorded 2 mentions for NewGenIvf Group and 1 mentions for IMAC. IMAC's average media sentiment score of 0.00 beat NewGenIvf Group's score of -0.23 indicating that IMAC is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
IMAC
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
NewGenIvf Group
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
NewGenIvf Group N/A N/A N/A

Summary

NewGenIvf Group beats IMAC on 7 of the 10 factors compared between the two stocks.

How does IMAC compare to Better Therapeutics?

Better Therapeutics (NASDAQ:BTTX) and IMAC (NASDAQ:BACK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Company Net Margins Return on Equity Return on Assets
Better TherapeuticsN/A N/A N/A
IMAC N/A N/A -325.44%

Better Therapeutics has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, IMAC has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500.

34.0% of Better Therapeutics shares are held by institutional investors. Comparatively, 5.8% of IMAC shares are held by institutional investors. 51.4% of Better Therapeutics shares are held by insiders. Comparatively, 12.3% of IMAC shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

IMAC has higher revenue and earnings than Better Therapeutics. IMAC is trading at a lower price-to-earnings ratio than Better Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Better TherapeuticsN/AN/A-$39.76M-$0.78N/A
IMAC$72.05K2.05-$9.42M-$3.12N/A

In the previous week, IMAC had 1 more articles in the media than Better Therapeutics. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Better Therapeutics. Better Therapeutics' average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Better Therapeutics Neutral
IMAC Neutral

Summary

Better Therapeutics beats IMAC on 5 of the 9 factors compared between the two stocks.

How does IMAC compare to UpHealth?

IMAC (NASDAQ:BACK) and UpHealth (NYSE:UPHL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
IMACN/A N/A -325.44%
UpHealth N/A N/A N/A

IMAC has higher earnings, but lower revenue than UpHealth. IMAC is trading at a lower price-to-earnings ratio than UpHealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
IMAC$72.05K2.05-$9.42M-$3.12N/A
UpHealth$130M0.00-$56.42M$1.47N/A

IMAC has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, UpHealth has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

In the previous week, IMAC had 1 more articles in the media than UpHealth. MarketBeat recorded 1 mentions for IMAC and 0 mentions for UpHealth. IMAC's average media sentiment score of 0.00 equaled UpHealth'saverage media sentiment score.

Company Overall Sentiment
IMAC Neutral
UpHealth Neutral

5.8% of IMAC shares are owned by institutional investors. Comparatively, 56.1% of UpHealth shares are owned by institutional investors. 12.3% of IMAC shares are owned by company insiders. Comparatively, 34.2% of UpHealth shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

UpHealth beats IMAC on 6 of the 9 factors compared between the two stocks.

How does IMAC compare to Aclarion?

Aclarion (NASDAQ:ACONW) and IMAC (NASDAQ:BACK) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Company Net Margins Return on Equity Return on Assets
AclarionN/A N/A N/A
IMAC N/A N/A -325.44%

5.8% of IMAC shares are owned by institutional investors. 12.3% of IMAC shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Aclarion has higher revenue and earnings than IMAC.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aclarion$75.73KN/AN/AN/AN/A
IMAC$72.05K2.05-$9.42M-$3.12N/A

In the previous week, IMAC had 1 more articles in the media than Aclarion. MarketBeat recorded 1 mentions for IMAC and 0 mentions for Aclarion. Aclarion's average media sentiment score of 0.00 equaled IMAC'saverage media sentiment score.

Company Overall Sentiment
Aclarion Neutral
IMAC Neutral

Summary

IMAC beats Aclarion on 3 of the 5 factors compared between the two stocks.

Get IMAC News Delivered to You Automatically

Sign up to receive the latest news and ratings for BACK and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BACK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BACK vs. The Competition

Export
MetricIMACSpecialty outpatient clinics IndustryMedical SectorNASDAQ Exchange
Market Cap$148K$148K$6.25B$11.87B
Dividend YieldN/AN/A2.73%5.21%
P/E Ratio-0.01N/A29.0428.48
Price / Sales2.052.05476.4860.89
Price / CashN/AN/A27.6236.52
Price / Book-0.06N/A9.676.67
Net Income-$9.42M-$9.42M$3.55B$332.64M
7 Day PerformanceN/AN/A1.70%2.01%
1 Month PerformanceN/AN/A5.62%9.19%
1 Year PerformanceN/AN/A34.42%39.59%

IMAC Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BACK
IMAC
N/A$0.04
-9.3%		N/AN/A$148K$72.05KN/A180
DHAC
Digital Health Acquisition
N/A$0.21
-5.9%		N/AN/A$764KN/AN/A2,021
NIVF
NewGenIvf Group
1.3653 of 5 stars		$1.96
+2.6%		N/AN/A$470K$4.73MN/AN/A
BTTX
Better Therapeutics
N/A$0.00
flat		N/AN/A$4KN/AN/A40
UPHL
UpHealth
N/A$0.00
flat		N/AN/A$2K$130MN/A1,750

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BACK) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel